1 completed, 1 recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
Follow HAD: new trials by email Literature Review of HAD trials Research Report on HAD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intermediate-dose HAD Regimen for CEBPA Double-mutated AML HAD, Daunorubicin+Cytarabine - AML | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 148 | 2024-08-13 | 2026-08-10 |
| Quality of Life Assessment Before and After Essure Removal SF-36, HAD, ANSM - Patients Presenting Essure Device Attributed Symptoms | Completed | University Hospital, Montpellier | 95 | 2017-01-10 | 2019-01-04 |
Institute of Hematology & Blood Diseases Hospital, China (1) · University Hospital, Montpellier (1)
China (1) · France (1)
Hui Wei, MD (1)